Marshall Wace LLP Has $34.25 Million Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Marshall Wace LLP grew its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 16.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 950,948 shares of the medical device company's stock after acquiring an additional 137,354 shares during the quarter. Marshall Wace LLP owned about 1.45% of Tandem Diabetes Care worth $34,253,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. AlphaQuest LLC boosted its stake in shares of Tandem Diabetes Care by 138.7% in the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock valued at $34,000 after buying an additional 541 shares during the period. Jones Financial Companies Lllp lifted its holdings in shares of Tandem Diabetes Care by 195.8% in the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock valued at $41,000 after purchasing an additional 748 shares during the last quarter. Assetmark Inc. lifted its holdings in shares of Tandem Diabetes Care by 77.5% in the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock valued at $44,000 after purchasing an additional 535 shares during the last quarter. McIlrath & Eck LLC acquired a new position in Tandem Diabetes Care in the 3rd quarter valued at about $52,000. Finally, Smartleaf Asset Management LLC increased its position in Tandem Diabetes Care by 163.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock valued at $65,000 after acquiring an additional 1,101 shares during the period.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on TNDM shares. Barclays dropped their target price on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. Morgan Stanley lowered shares of Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and decreased their target price for the stock from $45.00 to $22.00 in a research report on Wednesday, March 5th. Citigroup lowered shares of Tandem Diabetes Care from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $35.00 to $24.00 in a research report on Tuesday, March 4th. Royal Bank of Canada cut their price target on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating on the stock in a research note on Thursday, February 27th. Finally, Sanford C. Bernstein downgraded shares of Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and cut their target price for the company from $35.00 to $25.00 in a research note on Friday, February 28th. Eight analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Tandem Diabetes Care currently has a consensus rating of "Moderate Buy" and an average price target of $43.88.

Insider Buying and Selling at Tandem Diabetes Care

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos purchased 10,538 shares of Tandem Diabetes Care stock in a transaction that occurred on Friday, March 7th. The stock was acquired at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the acquisition, the chief operating officer now owns 10,538 shares of the company's stock, valued at approximately $190,948.56. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 2.20% of the company's stock.

Tandem Diabetes Care Trading Up 6.6 %

Shares of TNDM stock traded up $1.09 on Thursday, reaching $17.66. The company had a trading volume of 392,006 shares, compared to its average volume of 1,497,886. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. The stock has a market cap of $1.18 billion, a PE ratio of -9.14 and a beta of 1.52. The company has a 50-day moving average of $20.78 and a 200-day moving average of $29.60. Tandem Diabetes Care, Inc. has a 12 month low of $15.75 and a 12 month high of $53.69.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.